Patents by Inventor Joshua Rabinowitz

Joshua Rabinowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190211402
    Abstract: The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
    Type: Application
    Filed: February 28, 2019
    Publication date: July 11, 2019
    Applicant: Natera, Inc.
    Inventors: Joshua BABIARZ, Tudor Pompiliu CONSTANTIN, Lane A. EUBANK, George GEMELOS, Matthew Micah HILL, Huseyin Eser KIRKIZLAR, Matthew RABINOWITZ, Onur SAKARYA, Styrmir SIGURJONSSON, Bernhard ZIMMERMANN
  • Publication number: 20190211406
    Abstract: The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
    Type: Application
    Filed: March 20, 2019
    Publication date: July 11, 2019
    Applicant: Natera, Inc.
    Inventors: Joshua BABIARZ, Tudor Pompiliu CONSTANTIN, Lane A. EUBANK, George GEMELOS, Matthew Micah HILL, Huseyin Eser KIRKIZLAR, Matthew RABINOWITZ, Onur SAKARYA, Styrmir SIGURJONSSON, Bernhard ZIMMERMANN
  • Publication number: 20190203294
    Abstract: The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 4, 2019
    Applicant: Natera, Inc.
    Inventors: Joshua Babiarz, Tudor Pompiliu Constantin, Lane A. Eubank, George Gemelos, Matthew Micah Hill, Huseyin Eser Kirkizlar, Matthew Rabinowitz, Onur Sakarya, Styrmir Sigurjonsson, Bernhard Zimmermann
  • Publication number: 20190194758
    Abstract: The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: Natera, Inc.
    Inventors: Joshua BABIARZ, Tudor Pompiliu CONSTANTIN, Lane A. EUBANK, George GEMELOS, Matthew Micah HILL, Huseyin Eser KIRKIZLAR, Matthew RABINOWITZ, Onur SAKARYA, Styrmir SIGURJONSSON, Bernhard ZIMMERMANN
  • Publication number: 20190194759
    Abstract: The invention provides methods, systems, and computer readable medium for detecting ploidy of chromosome segments or entire chromosomes, for detecting single nucleotide variants and for detecting both ploidy of chromosome segments and single nucleotide variants. In some aspects, the invention provides methods, systems, and computer readable medium for detecting cancer or a chromosomal abnormality in a gestating fetus.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: Natera, Inc.
    Inventors: Joshua BABIARZ, Tudor Pompiliu CONSTANTIN, Lane A. EUBANK, George GEMELOS, Matthew Micah HILL, Huseyin Eser KIRKIZLAR, Matthew RABINOWITZ, Onur SAKARYA, Styrmir SIGURJONSSON, Bernhard ZIMMERMANN
  • Publication number: 20190185936
    Abstract: The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 20, 2019
    Applicant: Natera, Inc.
    Inventors: Joshua BABIARZ, Tudor Pompiliu CONSTANTIN, Lane A. EUBANK, George GEMELOS, Matthew Micah HILL, Huseyin Eser KIRKIZLAR, Matthew RABINOWITZ, Onur SAKARYA, Styrmir SIGURJONSSON, Bernhard ZIMMERMANN
  • Patent number: 10316362
    Abstract: The invention provides methods for simultaneously amplifying multiple nucleic acid regions of interest in one reaction volume as well as methods for selecting a library of primers for use in such amplification methods. The invention also provides library of primers with desirable characteristics, such as minimal formation of amplified primer dimers or other non-target amplicons.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: June 11, 2019
    Assignee: Natera, Inc.
    Inventors: Joshua Babiarz, Tudor Pompiliu Constantin, Lane A. Eubank, George Gemelos, Matthew Micah Hill, Huseyin Eser Kirkizlar, Matthew Rabinowitz, Onur Sakarya, Styrmir Sigurjonsson, Bernhard Zimmermann
  • Publication number: 20190134324
    Abstract: The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.
    Type: Application
    Filed: April 27, 2017
    Publication date: May 9, 2019
    Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventor: Joshua RABINOWITZ
  • Publication number: 20190046489
    Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
    Type: Application
    Filed: October 15, 2018
    Publication date: February 14, 2019
    Inventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
  • Patent number: 10130600
    Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 20, 2018
    Assignees: Memorial Sloan Kettering Cancer Center, The Trustees of Princeton University
    Inventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
  • Patent number: 9757407
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: September 12, 2017
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20160346309
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 1, 2016
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20160120832
    Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: May 5, 2016
    Applicants: Memorial Sloan Kettering Cancer Center, The Trustees of Princeton Univeristy
    Inventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
  • Publication number: 20150250800
    Abstract: Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.
    Type: Application
    Filed: May 26, 2015
    Publication date: September 10, 2015
    Inventors: Ron L. Hale, Peter M. Lloyd, Amy T. Lu, Patrik Munzar, Joshua Rabinowitz, Roman Skowronski
  • Publication number: 20150139949
    Abstract: The present invention provides methods and compounds for treating viral infections using combinations modulators of an HCV-associated component and modulators of host cell enzymes. The present invention also provides methods and compounds for treating viral infections using combinations of modulators of host cell enzymes and other agents that work, at least in part by modulating hos factors.
    Type: Application
    Filed: May 19, 2014
    Publication date: May 21, 2015
    Inventors: Emre KOYUNCU, Thomas E. SHENK, Joshua RABINOWITZ
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20140345635
    Abstract: The present disclosure generally relates to compositions, and related devices and methods, useful in vaporizing devices such as electronic cigarettes. The composition may comprise nicotine, at least one solvent, and at least one ion pairing agent, and may be vaporized to form a condensation aerosol, wherein inhalation of the aerosol allows for deposition of nicotine with the respiratory system, including deep lung deposition. The vaporizing device may comprise a vaporization unit, a battery, and an integrated circuit coupled to the battery, wherein the integrated circuit is configured to control the battery for rapid initial vaporization without overheating, producing thermal degradation products, or draining battery energy. The battery may operate with pulse width modulation for at least a portion of the time the vaporizing device is being used.
    Type: Application
    Filed: May 21, 2014
    Publication date: November 27, 2014
    Applicant: NJOY, Inc.
    Inventors: Joshua RABINOWITZ, Mark SCATTERDAY
  • Publication number: 20130065850
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: April 3, 2012
    Publication date: March 14, 2013
    Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Josh MUNGER, Bryson BENNETT, Thomas SHENK, Joshua RABINOWITZ
  • Patent number: 8158677
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: April 17, 2012
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20090239830
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.
    Type: Application
    Filed: June 2, 2008
    Publication date: September 24, 2009
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz